Varada S, et al. Treatment of coexistent psoriasis and lupus erythematosus. J Am Acad Dermatol. 2015 Feb;72(2):253-60.
- The coexistence of psoriasis with lupus erythematosus is rare and presents a therapeutic challenge.
- We present a review of 96 patients with coexistent disease and analyze treatment regimens in this population.
- The TNF-α inhibitors, and the newer biologics, ustekinumab and abatacept, may represent valid treatment options with little risk for clinical lupus flare.
Ferahbas A, et al. The coexistence of subacute cutaneous lupus erythematosus and psoriasis. J Eur Acad Dermatol Venereol. 2004 May;18(3):390-1.
“The coexistence of the two entities causes difficulty in choosing the right treatment. Phototherapy, which is a prime therapeutic option in psoriasis, is also one of the factors that may exacerbate LE.  On the other hand, antimalarial drugs used in the treatment of LE are responsible for psoriatic flares. Cyclosporin A improves regulation of the T lymphocyte population, which seems to be important in the pathogenesis of both
In conclusion, we believe that recognition of LE in psoriatic patients is very important. Screening tests of ANA and anti-SSA antibodies before starting phototherapy could be very helpful in these patients, because of the increased risk for photosensitivity.
We emphasize the necessity for further investigation of the relationship between these two diseases.”
Zalla MJ, Muller SA. The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Acta Derm Venereol Suppl (Stockh). 1996;195:1-15.
The coexistence of psoriasis with LE or other photosensitive disorders is rare in our patient population, occurring in 0.69% of patients with psoriasis and 1.1% of those with LE. PMLE was the most common cause of photosensitivity in psoriatic patients without LE, occurring in 32%. Less common causes included drug-related photosensitivity (thiazides and thiazide derivatives in four of the five cases), PUVA reactions, and photocontact reactions. The Goeckerman regimen or UVB applied in a cautious, well-controlled atmosphere was generally well tolerated in this group, including patients with PMLE. Photosensitivity occurred in 50% of our patients with psoriasis and LE, and it was secondary to LE in 70% of cases. Most patients were female and had SLE. Psoriasis developed first in 55% of the cases. Studies that were useful for distinguishing photosensitive from nonphotosensitive patients with SLE included determination of antibodies to extractable nuclear antigens (67% versus 14%), double-stranded DNA (64% versus 9%), and skin biopsy for direct immunofluorescence (58% versus 27%). Occasional patients have features suggestive of photosensitivity with or without signs or symptoms of LE. These patients may have atypical psoriatic plaques occasionally yielding routine histology diagnostic of psoriasis with direct immuno-fluorescence results suggestive of lupus. Frequently, connective tissue serology findings are positive, and affected patients require close follow-up for the development of LE. In patients with psoriasis and suspected photosensitivity, we recommend a careful history and examination, skin biopsy for routine histology and direct immunofluorescence, blood tests including determination of antibodies to antinuclear antibodies (Hep-2 substrate if negative on routine substrate), extractable nuclear antigens, and double-stranded DNA, and phototesting when indicated. Large-scale prospective studies are required before the most appropriate therapy for patients with psoriasis and LE can be recommended.
Children’s and Emory users, request article from Emily Lawson.
More PubMed results on SLE and psoriasis.